Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

34.33 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,398
Open	34.33
Bid (Size)	34.33 (200)
Ask (Size)	34.35 (500)
Prev. Close	34.33
Today's Range	34.33 - 34.33
52wk Range	12.46 - 37.34
Shares Outstanding	1,110,352,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight ↗

February 19, 2026

The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome.

Via Stocktwits

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

February 17, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Performance

YTD	+10.9%	+10.9%
1 Month	+9.5%	+9.5%
3 Month	+41.4%	+41.4%
6 Month	+82.6%	+82.6%
1 Year	+100.1%	+100.1%

More News

Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse

February 10, 2026

Via Finterra

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗

January 28, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Teva (TEVA) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Teva (TEVA) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗

February 05, 2026

Via The Motley Fool

Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗

February 03, 2026

Via The Motley Fool

Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗

January 29, 2026

Via The Motley Fool

Teva (TEVA) Q3 2025 Earnings Call Transcript ↗

January 28, 2026

Via The Motley Fool

Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology

January 28, 2026

Via Finterra

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

January 28, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

Via MarketMinute

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

January 27, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

Via MarketMinute

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

January 14, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Via Finterra

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Royalty Pharma plc

Via GlobeNewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗

December 27, 2025

Via The Motley Fool

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

December 24, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

December 24, 2025

Via The Motley Fool

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?

Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.

What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?

Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange

What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?

The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange

What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?

The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 34.33

When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?

The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 02/19/26 07:00 PM ET

What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?

The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 38.12B

How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?

Teva Pharmaceutical Industries Limited American Depositary Shares has 38B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.